VEGFA and colorectal cancer: Bevacizumab binds to soluble VEGF-A and prevents VEGF-A from binding to its receptors (VEGFR1 and VEGFR2) by steric hindrance, thereby reducing blood vessel density, vascular permeability, and liver metastases of colorectal cancer mediated by VEGFR1 and VEGFR2 [404].